Discovery of New Medicines in Academia

The Discovery of New Medicines in Academia, Volume 100 highlight examples of discoveries originating in academia that have been successfully translated into promising therapeutics that have advanced into clinical trials. Chapters in this release cover Design and Discovery of Itaconate prodrugs for Alopecia Areata, Hydroxyl-Dendrimer Delivery System for Neurological Disease, Development of allosteric modulators of G protein-coupled receptors for Psychiatric Disease, Targeting the constitutively active ERK1/2 signaling kinase for cancer, mRNA reprogramming of myeloid cells for tumor immunotherapy, Development of novel drugs targeting protein-protein interactions, and much more.Additional sections cover Neuro-steroids and analogs for the treatment of epilepsy, Development of inhibitors of eukaryotic translation, Discovery/development of antiviral, anticancer and/or anti-inflammatory agents, Discovery of novel anti-infective agents, Targeting proliferating cell nuclear antigen (PCNA) for cancer, and Implementation and Evolution of Quantitative Systems Pharmacology to Patient Digital Twins and Biomimetic Twins. - Provides recent examples of successful academic drug discovery projects in multiple disease areas, including oncology, immunology, neurology, and infectious diseases- Presents diverse examples, including small molecule, biologic, and nanomedicine-based therapeutics- Discusses innovative artificial intelligence platforms utilized in academic drug discovery efforts